Literature DB >> 15727936

In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.

Patrice K Held1, Eric C Olivares, Christina P Aguilar, Milton Finegold, Michele P Calos, Markus Grompe.   

Abstract

Phage phiC31 integrase is a site-specific recombinase that mediates efficient integration of circular extrachromosomal DNA into the host genome. Here, the integrase system was used to transfer the fumarylacetoacetate hydrolase (FAH) gene into the liver of mice affected with hereditary tyrosinemia type 1. Approximately 3.6% of transfected hepatocytes experienced an integration event. The absolute frequency of integration was 1/1374. A higher proportion of integrase-transfected FAH+ hepatocytes displayed abnormal morphology (bizarre nuclei, enlarged cells) on day 25 after gene transfer, compared to cells not receiving integrase. The increased frequency of these abnormal cells correlated with the amount of integrase plasmid administered, suggesting some form of integrase toxicity in Fah-/- livers. The abnormal hepatocyte appearance was transient and livers analyzed after longer selection (90 days) showed 60% repopulation with only normal healthy FAH+ hepatocytes. A total of seven different integration sites (accounting for >90% of integration) were identified. Serial transplantation of integrase-corrected hepatocytes to Fah-/- recipients was successful, suggesting long-term viability of corrected cells and persistent gene expression through many rounds of cell division. The stability of transgene expression, relatively high integration frequency, and significant site specificity that characterize the phiC31 integration system suggest that it may have utility in many gene therapy settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15727936     DOI: 10.1016/j.ymthe.2004.11.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.

Authors:  Christopher L Chavez; Annahita Keravala; Jacqueline N Chu; Alfonso P Farruggio; Vanessa E Cuéllar; Jan Voorberg; Michele P Calos
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Kinetics and longevity of ΦC31 integrase in mouse liver and cultured cells.

Authors:  Christopher L Chavez; Annahita Keravala; Lauren E Woodard; Robert T Hillman; Timothy R Stowe; Jacqueline N Chu; Michele P Calos
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

3.  The dynamic impact of hydrodynamic gene transfer on the immune system.

Authors:  Yan Wu; Shoubao Ma; Yonghao Liu; Lei Lei; Bo Hu; Haiyan Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo.

Authors:  Oliver G McDonald; Brian R Wamhoff; Mark H Hoofnagle; Gary K Owens
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 5.  Targeting site-specific chromosome integration.

Authors:  Patricia Nuno-Gonzalez; Hsu Chao; Kazuhiro Oka
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

Review 6.  Gene therapy of metabolic diseases.

Authors:  Alain Fischer; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 7.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

8.  Transgenic Xenopus laevis embryos can be generated using phiC31 integrase.

Authors:  Bryan G Allen; Daniel L Weeks
Journal:  Nat Methods       Date:  2005-12       Impact factor: 28.547

9.  In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice.

Authors:  Nicole K Paulk; Karsten Wursthorn; Annelise Haft; Carl Pelz; Gregory Clarke; Amy H Newell; Susan B Olson; Cary O Harding; Milton J Finegold; Raymond L Bateman; John F Witte; Ronald McClard; Markus Grompe
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

10.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.